Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Chimeric Antigen Receptor T Cells Targeting Glypican-3

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03884751
Recruitment Status : Completed
First Posted : March 21, 2019
Last Update Posted : February 24, 2022
Sponsor:
Collaborators:
NanJing PLA 81 Hospital
First Affiliated Hospital of Zhejiang University
RenJi Hospital
Information provided by (Responsible Party):
CARsgen Therapeutics Co., Ltd.

Brief Summary:
A Phase I Clinical Study of Chimeric Antigen Receptor T Cells Targeting Glypican-3 (CAR-GPC3 T Cells) in Patients with Advanced Hepatocellular Carcinoma

Condition or disease Intervention/treatment Phase
Hepatocellular Carcinoma Biological: CAR-GPC3 T Cells Phase 1

Detailed Description:

This is a phase I open-label, single-arm, multicenter clinical trial designed to observe and evaluate the safety, cell metabolokinetics, and efficacy of CAR-GPC3 T cells infused intravenously at single escalating doses in patients with advanced hepatocellular carcinoma.

Primary objectives:

- To evaluate the safety and tolerability of CAR-GPC3 T cells infused intravenously at escalating doses in patients with advanced hepatocellular carcinoma.

Secondary objectives:

  • To evaluate the metabolic kinetics of single infusion of CAR-GPC3 T cells
  • To evaluate the overall safety and tolerability of infusion of CAR-GPC3 T cells
  • To observe the efficacy of CAR-GPC3 T cells in the treatment of advanced hepatocellular carcinoma

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 9 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Clinical Study of Chimeric Antigen Receptor T Cells Targeting Glypican-3 (CAR-GPC3 T Cells) in Patients With Advanced Hepatocellular Carcinoma
Actual Study Start Date : August 15, 2019
Actual Primary Completion Date : May 28, 2021
Actual Study Completion Date : December 3, 2021

Arm Intervention/treatment
Experimental: CAR-GPC3 T Cells
The subjects are enrolled into 2 dose levels cohorts in sequence
Biological: CAR-GPC3 T Cells
CAR-GPC3 T Cells injection
Other Name: Chimeric Antigen Receptor T Cells Targeting Glypican-3




Primary Outcome Measures :
  1. Dose-limiting toxicity (DLT) [ Time Frame: After 28 days of single infusion ]
    Safety

  2. Maximum tolerated dose (MTD) [ Time Frame: After 28 days of single infusion ]
    tolerability


Secondary Outcome Measures :
  1. Pharmacokinetics (the copies of cells in vivo) [ Time Frame: Day0~Week 26 ]
    Pharmacokinetics is the"Implantation endpoint" which is defined as the number of copies of CAR-GPC3 DNA in peripheral blood at each visit after infusion until any two consecutive test results are negative or below the detection limit. It aims to calculate the Peak Plasma Concentration (Cmax)

  2. Pharmacokinetics ( the duration of survival of cells in vivo) [ Time Frame: Day0~Week 26 ]
    Duration of CAR-GPC3 T cell persistence is the period from the day of infusion to the first negative test result or result lower than the detection limit.It aims to calculate the area under the plasma concentration versus time curve (AUC)

  3. Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 [ Time Frame: Month 24 ]
    Adverse events up to 24 months of follow-up visit judged by the investigator to be associated with CAR-GPC3T cell infusion, such as abnormalities or changes in laboratory examinations, physical examinations, vital signs, etc.

  4. Antitumor efficacy-Progression-free survival (PFS) [ Time Frame: Month 24 ]
    The period from the day when the subject receives the infusion of cells to the first recorded tumor progression (whether treated or not) or death of any cause, which occurs first.

  5. Antitumor efficacy-Duration of response (DOR) [ Time Frame: Month 24 ]
    The period from the first evaluation of CR or PR to the first evaluation of PD(Progressive Disease) or death of any cause.

  6. Antitumor efficacy-Duration of disease control (DDC) [ Time Frame: Month 24 ]
    The period from the first evaluation of CR, PR, or SD to the first evaluation of PD or any cause of death.

  7. Antitumor efficacy-Overall survival (OS) [ Time Frame: Month 24 ]
    The period from the first infusion to any cause of death

  8. Antitumor efficacy-Objective response rate (ORR); [ Time Frame: Month 24 ]
    The number of cases in which tumor size is reduced to PR or CR / the total number of evaluable cases (%). In the event of PR or CR, the subjects should confirm it no less than 4 weeks after the first evaluation

  9. Antitumor efficacy-Disease control rate (DCR) [ Time Frame: Month 24 ]
    The number of cases in which response (PR + CR) and stable disease (SD) are achieved from the start of cell infusion/the total number of evaluable cases (%).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Aged 18 to 70 years, male or female;
  2. Patients with advanced hepatocellular carcinoma (HCC) diagnosed by histopathology or cytology who are not suitable for surgery or local treatment (including ablation, intervention, and radiotherapy), have developed progressive disease or intolerability after standard systemic therapies (including but not limited to systemic chemotherapy, molecular targeted therapy) and have no effective treatment at the time of enrollment;
  3. According to RECIST 1.1, patients have at least one evaluable target lesion, defined as: the longest diameter of non-lymph node lesion ≥ 10 mm, or the shortest diameter of lymph node lesion ≥ 15 mm); hepatic lesions require arterial phase contrast enhancement;
  4. In tumor tissue samples GPC3 is detected positive by immunohistochemistry (IHC);
  5. According to Barcelona Clinic Liver Cancer staging(BCLC), the patients are classified into Grade C or Grade B unsuitable for local treatment/progressive disease after local treatment;
  6. Expected survival is > 12 weeks;
  7. Cirrhosis status Child-Pugh score: Grade A;
  8. Eastern Cooperative Oncology Group(ECOG) Performance Status score: 0 to 1 point;
  9. Without active hepatitis B and/or Hepatitis C;
  10. Have venous accesses for pheresis;
  11. Acceptable routine blood test showing no contraindication to the lymphodepletion pretreatment;
  12. Adequate liver, renal, cardiovascular, respiratory function;
  13. Subjects of childbearing age must undergo a serum pregnancy test within 14 days before the initiation of the study and the result must be negative. In addition, they should be willing to use a reliable method of contraception during the trial (within 24 months (M24) after cell infusion); male subjects whose spouses are women of childbearing age should undergo sterilization surgery or agree to use a reliable method of contraception during the trial;
  14. Understand and sign informed consent.

Exclusion Criteria:

  1. Pregnant or breast-feeding women;
  2. HCV-RNA(Hepatitis C Virus RNA ), HIV antibodies or Syphilis Serological tests are positive;
  3. HBV(Hepatitis B) and HCV(Hepatitis C virus ) infection exist simultaneously;
  4. Any uncontrollable active infection
  5. Patients who had received systemic steroids or other immunosuppressive agents
  6. Previous or present hepatic encephalopathy;
  7. Current clinically significant ascites;
  8. ≥50% of the liver is replaced by tumor or portal vein main tumor thrombus, or tumor thrombus invasion of mesenteric vein / inferior vena cava;
  9. Metastases to the central nervous system and clinically significant central nervous system diseases;
  10. Patients with existing heart disease in need of treatment or hypertension that be poorly controlled
  11. Patients with known active autoimmune diseases which require to be treated with immunosuppressive agents including biological agents;
  12. Patients with a history of organ transplantation or waiting for organ transplantation (including liver transplantation);
  13. Patients with local treatments such as surgical treatment, interventional therapy, radiotherapy, ablation or systemic chemotherapy were performed for the studied disease within 2 weeks prior to apheresis;Or received immunotherapy (PD-1/ PD-L1 monoclonal antibody, see Section 15) or any Chinese herbal or proprietary medicine for the control of liver cancer within 1 week prior to apheresis;Or received sorafenib, regofenib, ramvastinib and other tyrosine kinase inhibitor targeted drugs within 1 week prior to apheresis;Targeted therapy with anti-angiogenic monoclonal antibodies such as bevacizumab or its analogue 4 weeks prior to apheresis;
  14. Patiens with previous treatment with targeted GPC3, TCR-T or CAR-T;
  15. Patients who previously received anti-PD-1/ PD-L1 monoclonal antibody therapy within 4 weeks prior to apheresis;
  16. Patients who had uncured malignant tumors in the past 5 years or at the same time, excluding in situ cervical cancer and skin basal cell carcinoma;
  17. Other serious illnesses that may limit subjects to participate in the trial (such as poorly controlled diabetes mellitus, severe cardiac insufficiency , myocardial infarction or unstable arrhythmia or unstable angina pectoris within the last 6 months, lung embolism, chronic obstructive pulmonary diseases, interstitial pulmonary diseases,gastric ulcer, a history of gastrointestinal bleeding or a clear tendency to gastrointestinal bleeding;
  18. According to the investigators' evaluation, patients are unable or unwilling to comply with the requirements of the study protocol.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03884751


Locations
Layout table for location information
China, Guangdong
Nanfang Hospital of Southern Medical University
Guangzhou, Guangdong, China, 510000
China, Henan
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China, 450000
China, Jiangsu
The 81st Hospital of Chinese PLA
Nanjing, Jiangsu, China, 210002
China, Shanghai
Renji Hospital Shang Hai Jiaotong Unversity of Medicine
Shanghai, Shanghai, China, 200001
Zhongshan Hospital of Fudan University
Shanghai, Shanghai, China, 200001
China, Zhejiang
The First Affiliated Hospital Zhejiang University
Hangzhou, Zhejiang, China, 310006
Sponsors and Collaborators
CARsgen Therapeutics Co., Ltd.
NanJing PLA 81 Hospital
First Affiliated Hospital of Zhejiang University
RenJi Hospital
Investigators
Layout table for investigator information
Principal Investigator: Qin shukui, Pro The 81st Hospital of PLA
Principal Investigator: Zhai bo, Pro RenJi Hospital
Layout table for additonal information
Responsible Party: CARsgen Therapeutics Co., Ltd.
ClinicalTrials.gov Identifier: NCT03884751    
Other Study ID Numbers: CT011-HCC-01
First Posted: March 21, 2019    Key Record Dates
Last Update Posted: February 24, 2022
Last Verified: February 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by CARsgen Therapeutics Co., Ltd.:
Hepatocellular Carcinoma
CAR-T
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma
Carcinoma, Hepatocellular
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Adenocarcinoma
Liver Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases